 The proposed Phase 4 study is designed to determine whether belatacept, in combination with other immunosuppressive agents rabbit antithymocyte globulin or alemtuzumab, mycophenolate mofetilEC mycophenolate sodium, may provide acceptable efficacy and safety in de novo kidney transplant recipients, in a regimen that provides simultaneous CNI freedom and early CSWD. 